Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter ...

Bill Sibold, Madrigal Pharmaceuticals CEO, joins 'Fast Money' to discuss Q2 earnings results, the weight loss space and their GLP-1 strategy.

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) stock declined 4% in pre-market trading Monday after the FDA approved Novo Nordisk’s (NYSE:NVO) Wegovy for treating adults with noncirrhotic metabolic ...

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Madrigal Pharmaceuticals ( NASDAQ: MDGL) has received conditional marketing approval from the European Commission for ...

Earlier this year, Madrigal Pharmaceuticals (NASDAQ: MDGL) launched its first product, Rezdiffra. It wasn't just an important breakthrough for the mid-cap biotech; Rezdiffra became the first ...

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...

Madrigal Pharmaceuticals did not generate any revenue from Rezdiffra in the first quarter since it started shipping the medicine in April. Also, the company is unprofitable, as one would expect.

About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease ...

Madrigal Pharmaceuticals' (NASDAQ: MDGL) shares are down by 27% over the past year, while the S&P 500 is up by 26%. However, this poor performance hardly reflects the progress the biotech has made ...